FUSN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FUSN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-05), Fusion Pharmaceuticals's share price is $21.45. Fusion Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.79. Hence, Fusion Pharmaceuticals's Price to Tangible Book Ratio of today is 7.69.
The historical rank and industry rank for Fusion Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
During the past 7 years, Fusion Pharmaceuticals's highest Price to Tangible Book Ratio was 7.69. The lowest was 0.78. And the median was 1.27.
A closely related ratio is called PB Ratio. As of today, Fusion Pharmaceuticals's share price is $21.45. Fusion Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.79. Hence, Fusion Pharmaceuticals's P/B Ratio of today is 7.69.
The historical data trend for Fusion Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | 1.66 | 0.78 | 0.87 | 3.44 |
Fusion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 0.87 | 1.19 | 1.59 | 0.95 | 3.44 |
For the Biotechnology subindustry, Fusion Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Fusion Pharmaceuticals's Price-to-Tangible-Book falls into.
Fusion Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2023 ) |
= | 21.45 | / | 2.791 | |
= | 7.69 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Teresa Marie Bitetti | director | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jeremy Bender | director | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
David D. Meek | director | 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
Dmitri Bobilev | officer: Chief Medical Officer | C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6 |
Steven Gannon | director | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8 |
John Valliant | director, officer: Chief Executive Officer | FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6 |
Christopher P Leamon | officer: Chief Scientific Officer | C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110 |
Mohit Rawat | officer: President and CBO | FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6 |
Donald A Bergstrom | director | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Philina Lee | director | C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
John J Crowley | officer: Chief Financial Officer | 251 BALLARDVALE STREET, WILMINGTON MA 01887 |
Healthcap Vii, L.p. | 10 percent owner | 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018 |
James J O'leary | officer: Chief Medical Officer | 830 WINTER STREET, WALTHAM MA 02452 |
From GuruFocus
By PRNewswire • 11-16-2023
By PRNewswire • 12-11-2023
By PRNewswire PRNewswire • 04-19-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 03-20-2023
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire • 09-13-2023
By PRNewswire • 08-08-2023
By PRNewswire • 09-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.